<p>Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.</p>

<ul>
	<li>The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and Pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months</li>
	<li>Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.</li>
	<li>In patients with concomitant HIV infection, the physician should be aware of current recommendation of CDC. It is possible these patients may require a longer course of treatment</li>
</ul>

<p>It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis.<br />
<br />
Pyrazinamide should only be used in conjunction with other effective antituberculous agents.</p>